Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Completed Phase 0 Trials for Fluorouracil (DB00544)

Also known as: Resectable Pancreatic Ductal Adenocarcinoma

Indication	Status	Phase
DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC))	Completed	0

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03970252	Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer	Treatment	Calcium (DB01373) Camptothecin (DB04690) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Levoleucovorin (DB11596) Nivolumab (DB09035) Oxaliplatin (DB00526)